390 results about "Elevated creatinine" patented technology

Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

The invention discloses a two-step enzyme measuring method and measuring reagents for creatinine in blood serum. The hydrogen peroxide generated by endogenous creatine is eliminated by utilizing catalase in a reagent 1 of the creatinine measuring reagents, and the catalase in the reagent 1 is suppressed by utilizing the catalase in a reagent 2 of the creatinine measuring reagents, so that the creatinine content in a sample is measured. The invention has the advantages that the phenomenon that the cost is increased because of oxidizing hydrogen peroxide by the catalase, so that the detection result is low in accuracy and precision is avoided.

The invention discloses a sepsis early prediction method based on machine learning. The method comprises the following steps: firstly, extracting clinical data, including demographic statistics (suchas age and gender), vital sign variables (such as heart rate and systolic pressure) and laboratory measurement indexes (such as creatinine and platelet count), of a patient within 24 hours after a patient enters an ICU by utilizing an electronic medical record, preprocessing the data, inputting the preprocessed data into an improved deep forest algorithm model for training, and outputting the disease probability of the patient after training optimization. And meanwhile, the algorithm model can also sort characteristic variables and output an early warning factor which has great influence on early prediction of sepsis. Finally, corresponding variables of the patient needing to be predicted are input into the trained model, so that early prediction of sepsis can be carried out on the patient. According to the invention, early prediction is carried out on sepsis based on a machine learning method, doctors can be assisted in making clinical decisions, and the prediction accuracy is improved.

The invention relates to a method for preparing bonito stick protein hydrolysate with an effect of reducing uric acid. The method comprises the following main steps of raw material heat treatment, restriction digestion, membrane separation-anion exchange chromatography-gel filtration chromatography separation, concentration and spray drying so as to obtain the bonito stick protein hydrolysate with an effect of reducing uric acid. The amino acid analysis indicates that the zymolyte peptide fragment primary amino acid sequence contains four amino acids, namely histidine, arginine, lysine and threonine, the total mass content of the four amino acids is 70 percent of the total amino acid content of zymolyte. MALDI-TOF-MS mass spectrum determines that the molecular weight of the main peptide effective ingredient is less than 700Da. In-vitro uric acid reduction experiments prove that the bonito stick protein hydrolysate has a remarkable effect of inhibiting generation of uric acid, and has an inhibition rate over 50 percent; an oteracil potassium molded hyperuricemic rat animal model indicates that the bonito stick protein hydrolysate can be used for remarkably reducing the level of serum uric acid and serum creatinine of rats, and shows a relatively good kidney protecting effect.

The invention discloses a serum creatinine detecting reagent, and belongs to the technical field of clinical in-vitro detection. According to the serum creatinine detecting reagent, gamma-Fe2O3 nano-particles are added into a reagent R1, so that the activity of peroxidase and the specificity to a substrate are enhanced, and the interferences of reducing substances, such as ascorbic acid, uric acid, glutathione and bilirubin, are reduced; meanwhile, the gamma-Fe2O3 nano-particles also serve as a catalyst of a reaction; the interference of endogenous creatine is effectively eliminated by the combination action of the gamma-Fe2O3 nano-particles and the peroxidase. In addition, the serum creatinine detecting reagent adopts N-ethyl-N-(2-hydroxy-3-sulfonated propyl)-3-methylaniline sodium salt (TOOS) as a chromogen, so that the reagent is more stable; the analysis sensitivity is high. The substances, such as lipase and lipoprotein lipase, are also added into the reagent R1, so that the influence of lipid turbidity can be removed effectively; therefore, the reagent of the invention has higher anti-jamming capability and stability.

The invention provides a kit for simultaneously detecting sodium, creatinine and microalbumin in urine. The kit comprises a reaction substrate with a sodium reaction hole, a creatinine reaction hole and a microalbumin reaction hole, and sodium diluent, creatinine diluents and standard colorimetric plates for sodium, creatinine and albumin. Reaction mats containing different configuration substrates and enzyme solutions are added to the three reaction holes, and semiquantitative detection on sodium, creatinine and microalbumin in urine is achieved. The kit is simple in preparation method, stable in performance and easy to store, color gradations corresponding to the content of sodium, creatinine and microalbumin in different kinds of urine are obvious, whether the salt amount of a detected person exceeds the standard or not and whether the kidney is damaged or not can be conveniently judged, and meanwhile the kit is suitable for being used by the clinical laboratory in a hospital and non-professional inspection personnel.

The invention generally relates to devices, systems and methods adapted for use by patients for monitoring their own dietary intake of sodium without any need of laboratory facilities or collection of blood samples. The systems utilize test strips for measuring the concentration of analytes in urine, specifically, chloride and creatinine. Urinary chloride concentrations, normalized by creatinine concentrations to reduce variability contributed mainly by changing states of hydration serve as a conveniently monitored surrogate for salt intake by subjects, especially patients with hypertension or congestive heart failure who must control their salt intake carefully.

A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

The invention belongs to the technical field of metabonomics, and provides Xiaoyao San metabolic markers in a biological sample, and a detection method and an application thereof. A pharmacological action mechanism of Xiaoyao San for treating depression is defined. The metabolic markers are 4-oxo hex-2-ene dioic acid, creatinine, L-cystathionine and acetylphosphate. A UPLC-Q-TOF/MS technology is adopted for analyzing the plasma and metabolic profile change of patients in a drug administration group and a control group of the Xiaoyao San, and then a multivariate statistical analysis method and an orthogonal partial least square discriminant analysis (OPLS-DA) method are adopted for screening the changes of the metabolic markers of the Xiaoyao San after 8-week treatment. The study is used as a first clinical metabonomics study of the Xiaoyao San; the influence of the metabolic level of the Xiaoyao San is found; the action mechanism of the Xiaoyao San is preliminarily illuminated in metabolic pathway; and a new method is provided for predicting the pharmacological mechanism of the Xiaoyao San for treating the depression.

The invention belongs to the technical field of biology and particularly discloses selenium-rich bifidobacterium longum as well as a preparation method and application thereof. The selenium-rich bifidobacterium longum prepared by virtue of the preparation method can be applied to the preparation drugs or foods for delaying the progress of diabetes mellitus and particularly can be applied to the preparation of the drugs or the foods for improving the physical signs and metabolism conditions of diabetes mellitus, the insulin signal pathways of a diabetes mellitus model, the pathological change of livers, pancreas and kidneys of patients with diabetes mellitus and the levels of serum creatinine and blood urea nitrogen of diabetes mellitus and preventing renal complications or renal function damage of diabetes mellitus.

The invention relates to an analysis method for quickly detecting urine creatinine by isotopic dilution, extractive electrospray ionization (EESI) and tandem mass spectrometry (MS/MS), and belongs to an analysis and detection means for a renal function biomarker. The method is characterized in that the detection means is that an EESI source is subjected to direct MS and MS/MS under normal pressure, linear trap quadrupole (LTQ)-MS/MS is set to be in a positive ion detection mode, the parameters of the EESI source, such as the composition of an electrospray solvent are adjusted, an isotopic dilution technology and a standard addition method are adopted in quantitative analysis, creatinine at gradient concentration and deuterated creatinine at fixed concentration are added into an urine sample, direct analysis is performed, a standard addition curve is drawn, and the concentration of the urine creatinine is obtained. The urine creatinine can be directly measured under the condition that the sample is not pretreated, and the defects of a long analysis period and low efficiency in the prior art are overcome. The method has the characteristics of quickness, accuracy, capability of resisting interference from a substrate, and the like, and is particularly suitable for the clinical research of renal disease (such as the early diagnosis of acute renal failure) and high-flux sample analysis.

The invention discloses a gold nanoparticle (AuNPs) biological sensor for detecting serum creatinine and a preparation method of the gold nanoparticle biological sensor. The preparation method comprises the steps of (1) preparing an AuNPs solution; (2) adding a GSH solution serving as an anti-aggregating agent for uniform mixing, and performing surface protection on the AuNPs; and (3) respectively adding standard serum creatinine solutions with different concentrations, and performing colorimetric and quantitative detection by using a fluorospectro photometer to obtain a relation curve between the serum creatinine concentration and the resonance light scattering (RLS) intensity so as to obtain the gold nanoparticle biological sensor. GSH can form a protection layer on the surface of AuNPs, so that the aggregation degree of AuNPs, which is caused by the adding of the serum creatinine is reduced; under proper GSH concentration, the serum creatinine solutions with different concentrations are added, so that an AuNPs solution system shows a gradual color change phenomenon; meanwhile, by the use of the relation between an AuNPs dispersing state or the aggregating degree and the RLS intensity, quantitative detection on the serum creatinine can be realized. The method for visual measurement and RLS intensity detection on the serum creatinine has the advantages of simplicity, quickness, high practicability and the like.

The invention relates to a urinary microalbumin (U-mALb)/urinary creatinine (U-Cr) integrated assay bigeminy strip, comprising a sample area and reaction areas. The U-mALb/U-Cr integrated assay bigeminy strip is characterized in that the sample area comprises a diffusion membrane and blood filtering membranes; the reaction areas comprise two detection windows, and the two detection windows can be used for detecting the ratios of the U-mALb and the U-Cr at the same time; the sample area for detecting the U-Cr by adopting a dry chemical method is arranged at the position where the reaction area is positioned, and the reaction area for detecting the U-mALb by using a colloidal gold dry type immune chromatography technology is arranged at a position which is 0.5cm away from the sample area. The different reaction areas contain different reagent pads, and the reagent pads respectively and independently react with corresponding components in urine. Synchronous detection can be realized only by dripping the random urine of a person to be tested into the sample area, so that the U-mALb/U-Cr integrated assay bigeminy strip is very suitable for medical institutions or individuals. By using the U-Cr for correction, the influence, caused by a sampling way and urine volume, on the excretory amount of urinary albumin can be eliminated, so that the U-mALb/U-Cr integrated assay bigeminy strip can provide more accurate evaluation for the albumin excretion rate and has a greater clinical significance for preventing diabetic nephropathy.

The invention is about a method of measuring the content of creatinine, and it also concerns the reagent box of creatinine diagnosis. This invention belongs to the field of medical testing and measuring technology. The reagent box is consisted of buffer solution, creatinine enzyme, creatine enzyme, sarcosine onidase, anaerooxidase and stabilizer. Firstly, we cause an enzyme-coupled reaction through mixing the sample and the reagent according to a certain proportion of volume; secondly, put the final reactant under the biochemical analyzer and test the absorbance variational situation (speed) of dominant wavelength; then we can get the content of creatinine. By using this invention, we can get the necessary measuring result with high sensitiveness and fine precision through biochemical analyzer, and the result would not be contaminated by material of internal and exogenous sources. Thus, this method can be conveniently promoted and applied.

The invention discloses an evaluation method for diet protein intake (DPI) of a chronic kidney disease (CKD) patient. Through research of relationships between a fasting serum blood urea nitrogen/creatinine ratio (BUN/Cr) and a single-time urine urea nitrogen/creatinine ratio (UUN/Cr) of a CKD third-phase patient with a stable illness state, and the diet protein intake (DPI), a DPI simple calculation formula based on the fasting serum BUN/Cr and/or random urine UUN/Cr is established. According to the final calculation formula, it is expected that a traditional method for evaluating the DPI through subsistence of the urine within 24 hours can be replaced by a biochemical detection result of a single-time blood or urine in clinical follow-up. Defects such as complexity, long detection time, poor accuracy, difficult sample subsistence or low patient compliance in the traditional method are overcome. Clinically, the method can be used for clinical follow-up, simple blood drawing or single-time urination, thereby evaluating the DPI. The method can be used for managing the diet protein intake of the CKD patient well, fast and conveniently.

The embodiment of the invention discloses a human serum creatinine content detecting reagent for resisting calcium dobesilate interference. The detection reagent comprises a first reagent, a second reagent and a third reagent, wherein the first reagent comprises sodium carbonate. The detection reagent is used for determining human serum creatinine based on an enzyme method, and besides, interference of calcium dobesilate drugs in serum can be avoided. The defect for detecting creatinine by a conventional enzyme method is overcome. The embodiment of the invention further provides a human serumcreatinine content detecting method for resisting calcium dobesilate interference.

The invention provides a traditional Chinese medicine composition for treatment of chronic renal diseases and chronic renal failure and its preparation method. The traditional Chinese medicine composition is prepared from the following raw material medicines by weight: 6-40 parts of rheum officinale, 10-95 parts of astragalus and 5-65 parts of salvia miltiorrhiza by a certain extraction and purification process into an injection, a freeze-dried powder injection or other oral preparations. Animal experiments confirm that, the traditional Chinese medicine composition can obviously improve the hemodynamic indexes of rats subjected to chronic glomerulonephritis, reduces serum IL-6, IL-8, and TNF (tumor necrosis factor)-alpha levels, significantly reduces serum creatinine and urea nitrogen and other indexes of rats subjected to hypertensive nephropathy, significantly reduces serum urea nitrogen and serum creatinine contents of rats subjected to the chronic renal failure, increases serum albumin content, and also can improve each hemodynamic index of rats subjected to the chronic renal failure; and pathological results show that the traditional Chinese medicine composition can improve and inhibit injures on kidney caused by the chronic renal diseases and chronic renal failure.

The invention discloses an application of physically-modified Chinese cobra venom in preparation of medicaments for treating acute and chronic nephrosis. The physically-modified Chinese cobra venom is obtained by dissolving Chinese cobra venom with deionized water, heating for denaturation and then performing renaturation; the heating temperature is controlled to be 50-100 DEG C, and the heating time is controlled to be 1 min-300 min. The invention finds that the heated and denaturated Chinese cobra venom can effectively reduce urine protein in acute and chronic nephrosis, reduce serum creatinine, and urea nitrogen, improve the pathological damage degree of the kidney, and recover kidney functions.